key: cord-0820234-0x5ln57x
authors: Hayashi, T.; Yaegashi, N.; Konishi, I.
title: Effect of RBD (Y453F) mutation in spike glycoprotein of SARS-CoV-2 on neutralizing IgG affinity.
date: 2021-02-01
journal: nan
DOI: 10.1101/2021.01.28.21250577
sha: 68e57a49ec43a8ffb61becc24022f69763c1b928
doc_id: 820234
cord_uid: 0x5ln57x

Background: Infection with receptor binding domain (RBD) mutant (Y453F) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from farmed minks is known to widely spread among humans. Methods: We investigated the characteristics of SARS-CoV-2 RBD Y453F mutant using three-dimensional structural analysis. We investigated the effect of the RBD Y453F mutant of SARS-CoV-2 on neutralizing antibodies in serum derived from Corona virus Disease 2019 (COVID-19) positive patients. Results: Our studies suggest that virus variants with RBD Y453F mutation partially escaped detection by four neutralizing monoclonal antibodies and neutralizing antibodies in serum. Conclusions: Consequently, raising a concern that infection of SARS-CoV-2 mutants that cause serious symptoms in humans may spread globally.

Mutations in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) can jeopardize the efficacy of potential vaccines and therapeutics against coronavirus disease-2019 (COVID-19).

Animals of the Mustelidae family, such as minks and ferrets can be infected with SARS-CoV-2 relatively easily compared with other mammals [1] . However, the reason why SARS-CoV-2 is extremely contagious to these animals remains to be elucidated. Nonetheless, it is clear that when several farmed minks kept in a high-density environment are infected with SARS-CoV-2, the virus proliferates in large numbers. Consequently, humans and minks may be at high risk of SARS-CoV-2 infection.

Natural selection "adaptation" in the coronavirus can occur during coronavirus amplification in vivo in farmed minks [2] . Natural selection in such viruses is observed by introduction of mutations in SARS-CoV-2 that are not observed during the growth process in humans [2, 3] . Infection with a mutant (Y453F) of SARS-CoV-2 from farmed minks is known to widely spread among humans 4 (Supplementary Figure 1) . We investigated the virological characteristics of this SARS-CoV-2 mutant (Y453F) using three-dimensional protein structural analysis (Spanner program, MOE protein program and Cn3D macromolecular structure viewer) [5, 6] .

Analyzes the three-dimensional structure of the binding site between mink and human ACE2 SARS-CoV-2 mutant has an amino acid mutation Y453F in the sequence encoding spike glycoprotein [4] . This SARS-CoV-2 mutant has been detected in approximately 300 viral sequences isolated from the European and Dutch population as well as in minks.

Data on the three-dimensional structure of the receptor binding domain (RBD) of the spike . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 1, 2021. ; https://doi.org/10.1101/2021.01.28.21250577 doi: medRxiv preprint glycoprotein of SARS-CoV-2 (PDB ENTITY SEQ 6VW1_1) was used in these studies [5] . Data Figure 4 ) that bind to the spike glycoprotein of SARS-CoV-2 was used in these studies [6] .

Using the Spanner program, we predicted the three-dimensional structure of the SARS-CoV-2 spike glycoprotein Y453F mutant based on PDB (ENTITY SEQ 6VW1_1). We investigated the binding of the spike glycoprotein Y453F mutant of SARS-CoV-2 to human angiotensin-converting enzyme 2 (ACE2) and determined the affinity of the spike glycoprotein Y453F mutant of SARS-CoV-2 to six neutralizing monoclonal antibodies using the MOE program (three-dimensional protein structure modeling, protein docking analysis: MOLSIS Inc., Tokyo, Japan) and Cn3D macromolecular structure viewer.

Analyses of protein contact residues and protein buried surface areas Protein contact residues were analyzed using the LigPlot+ program (v.1. 

The SeroFlash™ SARS-CoV-2 Neutralizing Antibody Assay Fast Kit (EpiGentek Group Inc., NY) contains all reagents necessary for quantitatively measuring SARS-CoV-2 neutralizing antibody level.

In this assay, RBD or RBD Y453F of SARS-CoV-2 spike protein is stably pre-coated onto microplate wells. His-tagged ACE2 is bound to the coated spike protein in the presence or absence of neutralizing antibody contained in the sample. The amount of the bound ACE2, which is proportional to ACE2 inhibition intensity, is then recognized by the Neutralizing Detection Complex containing anti-His is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 1, 2021. ; https://doi.org/10.1101/2021.01.28.21250577 doi: medRxiv preprint antibody and measured through an ELISA-like reaction by reading the absorbance in a microplate spectrophotometer at a wavelength of 450 nm. The neutralizing antibody level is inversely proportional to the optical density intensity measured. The higher the neutralizing antibody is, the lower the OD intensity is. Quantitative measurements of SARS-CoV-2 neutralizing antibody levels were performed according to the manufacturer's procedure. 

Studies by Spanner program revealed that the Y453F mutation did not affect the three-dimensional structure of conventional SARS-CoV-2 spike glycoproteins (Supplementary Figure 2) . From the present study, it was clarified that the binding property of the spike glycoprotein Y453F mutant to human ACE2 was slightly weaker than that of the conventional SARS-CoV-2 spike glycoprotein ( Figure 1A ). This was due to the replacement of Tyr at position 453 by Phe, which was unable to form a hydrogen bond with His at position 34 in human ACE2.

The present study revealed that the affinity between the spike glycoprotein Y453F mutant and four of the six monoclonal antibodies (CC12.1, CC12.3, COVA2-39, COVA2-04, CV07-250, CV07-270) examined was clearly weak compared with the conventional SARS-CoV-2 spike glycoprotein ( Figure   1B , Table 1 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 1, 2021. ; https://doi.org/10.1101/2021.01.28.21250577 doi: medRxiv preprint (Table 1, Supplementary Table 1) . From these results, the mutation of tyrosine at amino acid residue 453 of RBD to phenylalanine eliminated the inhibitory effect of the neutralizing antibody on binding between ACE2 and RBD.

It is considered that the affinity between the appropriate amino acid residues in the variable region of the antibody and the spike glycoprotein Y453F mutant was diminished owing to weak recognition of the monoclonal antibody to spike glycoproteins.

To the best of our knowledge, data on all SARS-CoV-2 mutants have not been published till date.

Therefore, it is unclear whether SARS-CoV-2 mutants detected in people working on mink farms are actually derived from the farmed minks. However, in the present study the subspecies of SARS-CoV-2 derived from farmed minks has been observed in the group of infected people, and the virus mutants that were inherited by infected individuals (Supplementary Figure 5) .

and animals susceptible to infection through easy propagation in the host, thereby making it difficult to identify the effects of therapeutic agents or vaccines for COVID-19. Moreover, the spread of SARS-CoV-2 variants mediated by millions of infected farmed mink is uncontrolled; consequently, raising a concern that infection of SARS-CoV-2 mutants that cause serious symptoms in humans may spread globally. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 1, 2021. ; https://doi.org/10.1101/2021.01.28.21250577 doi: medRxiv preprint and viruses so far, mankind has not stopped the mutation of viruses. More than 50 countries and territories around the world have strict restrictions on entry from the UK, South Africa and Brazil [11] . First, people around the world should reaffirm the importance of wearing masks, hand hygiene, and social distance. 

All authors are receiving medical ethics education. In addition, this study has been approved as a clinical medical study at each medical facility. The human serum samples used in this study were purchased from RayBiotecn life, and therefore Informed consent from the patient is not required.

Data are available on various websites and have also been made publicly available (more information can be found in the first paragraph of the Results section).

This study was reviewed and approved by the Central Ethics Review Board of the National Hospital Organization of Japan (Meguro, Tokyo, Japan). The approved number for this study is 50-201504. In order to carry out this research, the authors attended a research ethics education course (e-APRIN) conducted by Association for the Promotion of Research Integrity (APRIN; Shinjuku, Tokyo, Japan).

The approved numbers of e-APRIN are AP0000151756, AP0000151757, AP0000151758, AP0000151769.

The authors declare no potential conflicts of interest. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

T.H. performed most of the experiments and coordinated the project. T.H. and N.Y. conceived the study and wrote the manuscript. N.Y. and I.K. provided with information on clinical medicine and oversaw the entire study.

The transparency document associated with this article can be found in the online version at http://. 8 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 1, 2021. ; https://doi.org/10.1101/2021.01.28.21250577 doi: medRxiv preprint 

The interaction between Angiotensin-converting enzyme 2 (ACE2) (green) and residues of the conventional receptor binding domain (RBD) or RBD Y453F mutant (purple) is shown using the three-dimensional structure model. It is speculated that the Y453 amino acid residue of the conventional RBD is hydrogen-bonded to the H34 amino acid residue of human ACE2. However, the binding between the F453 amino acid residue of the RBD mutant and the H34 amino acid residue of human ACE2 is presumed to be slightly weak. From these results, the affinity between the spike glycoprotein of the RBD Y453F mutant and human ACE2 is presumed to be slightly weak compared with the conventional RBD. (B) The interaction between the heavy chain (purple) and light chain (brown) of neutralizing monoclonal antibody CC12.1 and residues of the conventional RBD or RBD Y453F mutant (green) is shown using the three-dimensional structure model. It is speculated that the Y453 amino acid residue of the conventional RBD is hydrogen-bonded to the D92 amino acid residue of the light chain and D97 amino acid residue of the heavy chain of neutralizing monoclonal antibody CC12.1. However, the binding between the F453 amino acid residue of the RBD mutant and the D92 and D97 amino acid residues of neutralizing monoclonal antibody CC12.1 is presumed to be weak. From these results, the affinity between the spike glycoprotein of the RBD Y453F mutant and neutralizing monoclonal antibody CC12.1 is presumed to be low compared with the conventional RBD. The three-dimensional structure models are shown by Cn3D macromolecular structure viewer. Detailed experimental results are indicated in Supplementary data. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 1, 2021. ; https://doi.org/10.1101/2021.01.28.21250577 doi: medRxiv preprint Table 1 . Affinity of RBD or RBD Y453F in spike glycoprotein of SARS-CoV-2 with neutralizing antibodies or serum from each patient. The binding of RBD Y453F mutant in the spike glycoprotein of SARS-CoV-2 to human ACE2 and the affinity of RBD Y453F mutant in the spike glycoprotein of SARS-CoV-2 to six neutralizing monoclonal antibodies were investigated using the MOE program (three-dimensional protein structure modeling, protein docking analysis: MOLSIS Inc., Tokyo, Japan) and Cn3D macromolecular structure viewer. Binding energy calculated by the MOE program is shown in the table. Quantitative measurement of SARS-CoV-2 neutralizing antibody levels is examined by using SeroFlash ™ SARS-CoV-2 Neutralizing Antibody Assay Fast Kit (EpiGentek Group Inc. NY). The strong affinity for RBD was shown in IgG in the serum of 14 of the 21 COVID-19-positive patients. However, no affinity for RBD Y453F was shown in the serum IgG of 19 of the 21 COVID-19-positive patients. Weak affinity for both RBD and RBD Y453F was shown in IgG in the serum of 2 of the 21 COVID-19-positive patients. No affinity for RBD or RBD Y453F was shown in IgG in the serum of all 10 COVID-19 negative subjects. Detailed experimental results are indicated in Supplementary  Table 1 . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 1, 2021. ; https://doi.org/10.1101/2021.01.28.21250577 doi: medRxiv preprint

Coronavirus rips through Dutch mink farms, triggering culls

Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans

Subspecies of SARS-CoV-2 from farmed minks might be a threat to humans

COVID mink analysis shows mutations are not dangerous-yet

Structural basis of receptor recognition by SARS-CoV-2

Structural basis of a shared antibody response to SARS-CoV-2

Emergencies preparedness, response. WHO Disease Outbreak News